Researchers consolidate the diverse nutritional and medicinal benefits of seaweeds, touting their potential in food, nutraceuticals, and pharmaceuticals. The study also highlights challenges and opportunities in industrial applications, calling for more research to optimize extraction and refinement processes.
What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study? (Part 2) – Psychedelic Alpha
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. Subscribe AnnuallySubscribe Monthly Already
August 28, 2024